VEGF targeting therapies may exert broad anti-tumor and anti-angiogenic effects through direct inhibition of vessel growth inducing regional cancer cell death, induction of endothelial cell apoptosis through activation of BCL2 or Akt signaling, and stopping the recruitment of hematopoietic or endothelial progenitor cells for new vessel formation [19,20,21,22]. The gene discussed is VEGFA; the disease is cancer.